Skip to content
preclinicalImmune & Inflammation

Crystagen

Also known as: Thr-Glu-Gly, TEG tripeptide, Immune tripeptide bioregulator

Crystagen (Thr-Glu-Gly) is a synthetic tripeptide immune bioregulator from Khavinson's laboratory. This three-amino-acid peptide is proposed to target immune cell gene expression, enhancing innate and adaptive immune responses. Preclinical studies suggest it modulates cytokine production and lymphocyte activation. As a tripeptide, it sits between the dipeptide bioregulators (Thymogen, Vilon) and the tetrapeptide series (Epithalon, Cardiogen) in Khavinson's peptide hierarchy.

2 cited references·2 researched benefits

Quick Answer

Crystagen (Thr-Glu-Gly) is a synthetic tripeptide immune bioregulator proposed to enhance immune cell function through gene expression modulation. Part of the Khavinson bioregulator family, this three-amino-acid peptide targets lymphocyte activation and cytokine production. Preclinical research reports immune-enhancing effects in aged animal models. It remains a research compound without regulatory approval or robust clinical evidence.

Key Facts

Mechanism
Crystagen is proposed to interact with DNA regulatory regions in lymphocytes and natural killer cells, modulating genes involved in immune activation, cytokine production (IL-2, IFN-gamma), and cell-mediated immunity. The tripeptide may influence histone modifications at immune gene loci, promoting euchromatin formation and increased transcription of immune defense genes.
Research Status
preclinical
Half-Life
~30–60 minutes
Molecular Formula
C₉H₁₅N₃O₆
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Immune enhancement — may boost lymphocyte and NK cell function in preclinical modelspreliminary
  • Cytokine modulation — preclinical data suggests favorable shifts in cytokine profilespreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Research use only10–100 mcgVariablePreclinical research compound. No approved therapeutic dosing.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • No significant adverse effects reported in preclinical studiesrare

Frequently Asked Questions

How does Crystagen compare to proven immunomodulators?
Proven immunomodulators like thymosin alpha-1 have extensive clinical trial data, defined mechanisms, and regulatory approvals. Crystagen has primarily preclinical evidence from Khavinson's laboratory. For immune enhancement, well-established approaches (vaccines, interferons, thymosin alpha-1) have far more evidence supporting their use.

References

  1. 1
    Tripeptide immune bioregulators: effects on lymphocyte function(2009)
  2. 2
    Peptide bioregulators of immune function(2011)PubMed ↗

Latest Research

Last updated: 2026-02-19